>40% sales growth expected in Q4. EBITDA up 2.6-5.5% for '23e-'25e. HOLD maintained, TP revised up to SEK 318 (284).
18 Jan 2024
High activity level in Q4e
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
High activity level in Q4e
- Published:
18 Jan 2024 -
Author:
ABGSC Healthcare Research | Sten Gustafsson -
Pages:
13 -
>40% sales growth expected in Q4. EBITDA up 2.6-5.5% for '23e-'25e. HOLD maintained, TP revised up to SEK 318 (284).